Updates are available Correction dated 2022-12-22
Click to view Correction: https://doi.org/10.1038/s41408-022-00775-6
-
Authors
Hampel, Paul J. http://orcid.org/0000-0003-1292-3024
Parikh, Sameer A. http://orcid.org/0000-0002-3221-7314
- License Information
-
More Information
Article History
Received: 25 October 2022
Revised: 8 November 2022
Accepted: 10 November 2022
First Online: 29 November 2022
Change Date: 22 December 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41408-022-00775-6
Competing interest
: Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria has been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Genentech, Amgen, TG Therapeutics, Novalgen Limited, and AbbVie for Sameer A. Parikh’s participation in consulting activities/advisory board meetings.
